Medincell Stock Drops Over 3% as Annual Results Approach
The biotech company from Montpellier experiences a sharp decline mid-session, going against its recent momentum. The stock struggles at the bottom of the SBF 120 while the Parisian market itself moves into negative territory. This movement occurs just days before a highly anticipated accounting event.
The stock downgrades below its 20-day moving average and ranks among the steepest declines of the SBF 120
Medincell stock drops 3.24% to €26.90 during the session, down from €27.80 the previous day. The stock is among the sharpest declines in the SBF 120, which itself has fallen by 0.35%. This downturn breaks the momentum that began last week when the stock had risen nearly 3% on Monday according to a previous report. The price has fallen below its 20-day moving average (€27.23), with a gap of 1.21% below this short-term benchmark. However, the backdrop remains favorable over the long term: the performance is up +23.3% over three months and +68.1% over a year. The RSI at 57 remains neutral, showing no signs of exhaustion.
A technical retreat before the announcement of annual results on June 16
Today's decline occurs just a few sessions before the announcement of the annual accounts (fiscal year April 2025-March 2026), scheduled for June 16. This event will be an opportunity for the biotech to detail the progress of its partnerships, notably the one with Teva on extended-release olanzapine, whose file was accepted by the EMA on May 22. Despite today's drop, the stock maintains a significant cushion over its long-term benchmarks: it is 6.03% above its MM50 (€25.37) and 5.16% above its MM200 (€25.58). The medium-term structure remains bullish, even though the price has moved away from the resistance of €28.72 reached at the end of May. The annual publication, expected on June 16, will deliver the figures and roadmap for the new fiscal year.
